Crohn's disease successfully treated with the paleolithic ketogenic diet

Article · September 2016
DOI: 10.5348/ijcri-2016102-CR-10690

CITATIONS
3

READS
12,312

5 authors, including:

Csaba Tóth
Paleomedicina Hungary
18 PUBLICATIONS 69 CITATIONS
SEE PROFILE

Andrea Dabóczi
Paleomedicina Hungary
2 PUBLICATIONS 3 CITATIONS
SEE PROFILE

Zsofia Clemens
Paleomedicina Hungary
52 PUBLICATIONS 1,105 CITATIONS
SEE PROFILE

Some of the authors of this publication are also working on these related projects:

Hippocampal and parahippocampal activity during sleep in humans View project

Serum cholesterol and memory View project

All content following this page was uploaded by Csaba Tóth on 22 August 2016.
The user has requested enhancement of the downloaded file.
Crohn’s disease successfully treated with the paleolithic ketogenic diet

Csaba Tóth, Andrea Dabóczy, Mark Howard, Nicholas J. Miller, Zsófia Clemens

ABSTRACT

Introduction: Crohn’s disease is regarded as having no curative treatment. Previous reports on dietary therapy of Crohn’s disease indicate no major success.

Case Report: Here we report a severe case of Crohn’s disease where we successfully applied the paleolithic ketogenic diet. Dietary therapy resulted in resolution of symptoms, normalized laboratory parameters as well as gradual normalization of bowel inflammation as evidenced by imaging data and normalization of intestinal permeability as shown by the polyethylene glycol (PEG 400) challenge test. The patient was able to discontinue medication within two weeks. Currently, he is on the diet for 15 months and is free of symptoms as well as side effects.

Conclusion: We conclude that the paleolithic ketogenic diet was feasible, effective and safe in the present case.
ABSTRACT

Introduction: Crohn’s disease is regarded as having no curative treatment. Previous reports on dietary therapy of Crohn’s disease indicate no major success. Case Report: Here we report a severe case of Crohn’s disease where we successfully applied the paleolithic ketogenic diet. Dietary therapy resulted in resolution of symptoms, normalized laboratory parameters as well as gradual normalization of bowel inflammation as evidenced by imaging data and normalization of intestinal permeability as shown by the polyethylene glycol (PEG 400) challenge test. The patient was able to discontinue medication within two weeks. Currently, he is on the diet for 15 months and is free of symptoms as well as side effects. Conclusion: We conclude that the paleolithic ketogenic diet was feasible, effective and safe in the present case.

Keywords: Crohn’s disease, Dietary therapy, Inflammatory bowel disease, Ketogenic diet, Paleolithic diet

INTRODUCTION

Crohn's disease, an inflammatory disease of the bowel, is regarded as having no cure [1]. Standard treatment which involves steroids, immunosuppressants and biological therapy is aimed at reducing symptoms [1]. Periods of flares and remissions typically alternate, however, the overall course of the disease is progressive. A set of ecological evidence, including a discrepancy between westernized and non-westernized countries in the occurrence of the disease, raises the possibility of lifestyle and/or dietary factors in the etiology of the disease [2]. There have been several attempts to use a dietary intervention in Crohn’s disease such as the specific carbohydrate diet [3] and the anti-inflammatory diet [4] as well as elimination-reintroduction diets [5]. Although clinical improvements and reduction of medicines have been reported being associated with these diets we are not aware of any diet inducing complete remission and long-term freedom of medicines at the same time.

The authors of the present report are using a diet referred to as the paleolithic ketogenic diet in the treatment of chronic conditions. So far we have published
cases of successful treatment of diabetes type 1 [6, 7] and type 2 [8], epilepsy [9, 10] as well as other conditions [11].

CASE REPORT

Diagnosis

The 14-year-old boy presented with fatigue, low grade fever, iron deficiency anemia, lower abdominal tenderness and perianal dermatitis. He was of short stature for his age. On 30 September 2013 upper and lower endoscopy was performed. The latter showed ulcerative lesion in the terminal ileum. Biopsy was taken from multiple sites and histopathology showed severe inflammation of the terminal ileum and the Bauhin’s valve. Signs of mild-to-moderate degree aspecific inflammation were seen in the colon. On laboratory workup inflammatory marker C reactive protein (CRP) was elevated (58 mg/L). He was diagnosed with Crohn’s disease.

Standard treatment

At the time of diagnosis onset (on 07 October 2013) the patient was started on mesalazine, metronidazole and pantoprazole. Within ten days, ciprofloxacin and probiotics were added. Given that no improvement was seen immunosuppressant therapy was initiated on 13 November 2013 with azathioprine together with methylprednisolone, potassium citrate, calcium and vitamin D. Given that disease progressed, a year after diagnosis onset (on 25 September 2014), biological therapy was initiated: five cycles of adalimumab were given each two weeks apart. The condition of the patient further deteriorated and therefore on 07 November 2014 exclusive formula feeding was initiated. At this time mesalazine, multivitamin, vitamin D3 and calcium were discontinued. Pantoprazole was discontinued within two weeks. Formula-based nutrition resulted in the resolution of abdominal pain but other symptoms persisted (Table 1, Figures 1 and 2).

Laboratory data

As the disease progressed iron deficiency anemia of the patient worsened. Thrombocyte number showed a decreasing tendency across the course of the standard treatment. Level of inflammatory markers CRP and erythrocyte sedimentation rate (ESR) dropped when initiating the immunosuppressant therapy and steroid but increased thereafter (Table 1, Figure 2).

Imaging

At the time of the diagnosis ultrasound examination performed on 07 October 2013 showed thickening of the terminal ileum and that of the small intestine at multiple sites. No thickening of the colon was seen. Three further follow-up ultrasound examinations were carried out during the next year. This showed progression of the disease as reflected by increasing diameter of the thickened bowel wall and an increasing intensity of hypervascularization. The last ultrasound out of the four (on 7 November 2014) already indicated the thickening of nearly all bowel segments including the colon ascendens and the colon transversum. Figure 3 shows as the largest diameter of the terminal ileum changed between 7 October 2013 and 7 November 2014.

Magnetic Resonance Enterography

Magnetic resonance enterography performed five weeks after diagnosis onset (on 12 November 2013) indicated thickening of the small intestinal wall at multiple locations. A follow-up magnetic resonance enterography 13 months later, on 16 December 2014, showed an increase in the variability in the diameter of the bowel lumen and narrowing of the lumen (Figure 4). Due to the narrowing the patient was offered surgery in December 2014 which he refused.

Symptoms

Abdominal cramps as well as episodes of low grade fever lessened when initiating the immunosuppressant therapy together with steroid. However, within three months the patient developed bilateral knee pain as a new symptom. Later on his appetite deteriorated. At 12 months after diagnosis onset abdominal cramps increased and episodes of low grade fever returned. The patient reported fatigue along with a deterioration in his school performance. Following the onset of the biological therapy all symptoms persisted. Following the fourth cycle of adalimumab strong abdominal pain emerged abruptly which persisted for several hours. Given this experience and the overall ineffectiveness of the biological therapy the patient decided to stop it. He was put on exclusive enteral nutrition which resulted in a lessening of his abdominal cramps but other symptoms persisted.

Dietary advices while on the standard therapy

The patient was advised to follow a diet free of lactose and low in fat and fibers. Analysis of his diet-symptom diary did not show any consistent association between symptoms and food items.

Intervention with the paleolithic ketogenic diet

Given the ineffectiveness of standard therapies the parents of the child were seeking for alternative options. When we first met the patient he reported bilateral pain and swelling of the knee, frequent episodes of fever and night sweats as well as fatigue. He looked pale. We offered the paleolithic ketogenic diet along with close monitoring of the patient. The patient started the diet on 4 January 2015. The diet is consisting of animal fat, meat, offal and eggs with an approximate 2:1 fat : protein
Urinary ketones were positive on each occasion. Blood glucose was between 5 and 5.4 mmol/l. Renal and liver function as well as ions were normal. His severe iron deficiency anemia was reversed already on the fourth week of the diet. iron level increased from 3.6 μmol/L to 12.1 μmol/L. Inflammatory markers including ESR and CRP decreased significantly: at four weeks CRP was 3.75 mg/L while ESR was 3 mm/h (Figure 2). Thereafter inflammatory markers elevated to some extent. Thrombocyte number was already low before diet onset but decreased further following diet onset. The last laboratory follow-up, however, on 14 December 2015, indicated an increase in thrombocyte number (Table 2.).

**Imaging**

Ultrasound examination of the abdomen was carried out five times during follow-up and was performed by the same investigator. The first examination following the onset of the paleolithic ketogenic diet, on 29 January 2015, showed significant improvement. Although wall of the terminal ileum was still thickened hypervascularization was no longer present. Thickening was still seen in the coecum and the ileum but not in the other regions which were described as being affected on the preceding ultrasound examination. A follow-up exam on 09 April 2015 showed further improvement: thickening of the wall of the terminal ileum decreased and no abnormal was seen in any other regions. A next ultrasound which was made following eating the “paleo cakes” showed thickening of the wall of the terminal ileum to as much as 6 mm. On the next examination, on 19 Jun 2015, thickening of the terminal ileum decreased to 4.5 cm. Three months later, on 17 September 2015, the examination showed no abnormality (Figures 2 and 3).

**Intestinal permeability test**

Intestinal permeability was assessed using a polyethylene glycol (PEG 400) challenge test based on the method of Chadwick et al. [12]. PEG 400 contains a mixture of inert water soluble molecules of 11 different sizes that are absorbed independently of dose, but which display decreasing mucosal transport with increasing molecular size. PEG 400 is also nontoxic, not degraded by intestinal bacteria, not metabolized by tissues, and rapidly excreted in urine. After a 3.0-gram oral dose of PEG, the subject makes a six-hour urine collection. The PEG fractions are acetylated with acetic anhydride, using pyridine as a catalyst, and then quantitated by capillary gas-liquid chromatography. The percentage of each fraction of PEG excreted over 6 hours is calculated.

PEG 400 challenge test performed at four months on the diet (on 18 May 2015) showed increased permeability to PEG between 242 and 418 molecular weight. A follow-up test performed at 10 months on the diet (on 26 November 2015) showed no abnormal intestinal permeability (Figure 6).
### Table 1: Laboratory data while on a standard diet and corresponding medications, Dashes indicate that a given parameter was not measured

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>9.6</td>
<td>7.5</td>
<td>23.2</td>
<td>13.8</td>
<td>6.3</td>
<td>7.6</td>
<td>7.7</td>
<td>4.5-11.5 G/L</td>
</tr>
<tr>
<td>RBC</td>
<td>5.5</td>
<td>5.3</td>
<td>5.6</td>
<td>5.5</td>
<td>4.2</td>
<td>4.4</td>
<td>4.7</td>
<td>4.5-5.9 T/L</td>
</tr>
<tr>
<td>Hgb</td>
<td>117</td>
<td>113</td>
<td>130</td>
<td>133</td>
<td>110</td>
<td>119</td>
<td>132</td>
<td>135-170 g/L</td>
</tr>
<tr>
<td>Hct</td>
<td>0.38</td>
<td>0.36</td>
<td>0.41</td>
<td>0.41</td>
<td>0.33</td>
<td>0.35</td>
<td>0.39</td>
<td>0.41-0.51 L/L</td>
</tr>
<tr>
<td>Thrombocyte</td>
<td>252</td>
<td>285</td>
<td>311</td>
<td>168</td>
<td>128</td>
<td>240</td>
<td>166</td>
<td>150-400 G/L</td>
</tr>
<tr>
<td>CRP</td>
<td>23.1</td>
<td>21.1</td>
<td>2.6</td>
<td>2.4</td>
<td>12.3</td>
<td>46.7</td>
<td>19.6</td>
<td>0-5 mg/L</td>
</tr>
<tr>
<td>ESR</td>
<td>12</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>14</td>
<td>25</td>
<td>15</td>
<td>0-15 mm/h</td>
</tr>
<tr>
<td>T. protein</td>
<td>59</td>
<td>53.9</td>
<td>57.9</td>
<td>54.4</td>
<td>58.3</td>
<td>61.6</td>
<td>57.3</td>
<td>57-80 g/L</td>
</tr>
<tr>
<td>Carbamide</td>
<td>0.8</td>
<td>1.7</td>
<td>4.2</td>
<td>5</td>
<td>3.5</td>
<td>2.7</td>
<td>2.8</td>
<td>2.8-7.2 mmol/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>49</td>
<td>47</td>
<td>44</td>
<td>58</td>
<td>41</td>
<td>45</td>
<td>56</td>
<td>53-100 μmol/L</td>
</tr>
<tr>
<td>Sodium</td>
<td>140</td>
<td>142</td>
<td>140</td>
<td>136</td>
<td>-</td>
<td>-</td>
<td>143</td>
<td>135-145 mmol/L</td>
</tr>
<tr>
<td>Potassium citrate</td>
<td>4.5</td>
<td>4.1</td>
<td>3.9</td>
<td>4.1</td>
<td>-</td>
<td>-</td>
<td>4.5</td>
<td>3.2-5.1 mmol/L</td>
</tr>
<tr>
<td>GOT</td>
<td>11</td>
<td>18</td>
<td>11</td>
<td>10</td>
<td>17</td>
<td>15</td>
<td>15</td>
<td>0-50 U/L</td>
</tr>
<tr>
<td>GPT</td>
<td>6</td>
<td>11</td>
<td>12</td>
<td>8</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td>0-50 U/L</td>
</tr>
<tr>
<td>GGT</td>
<td>13</td>
<td>23</td>
<td>23</td>
<td>15</td>
<td>11</td>
<td>15</td>
<td>9</td>
<td>0-55 U/L</td>
</tr>
<tr>
<td>Iron</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>6.9</td>
<td>3.6</td>
<td>-</td>
<td>12.5-32 μmol/L</td>
</tr>
<tr>
<td>formula feeding</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>adalimumab</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>multivitamin</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>calcium</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vitamin D3</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>potassium citrate</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>methylprednisolone</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>azathioprine</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>probiotics</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ciprofloxacin</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pantoprazole</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>metronidazole</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mesalazine</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSION

Here we report a case where Crohn’s disease was reversed by the paleolithic ketogenic diet.

Disease symptoms began to improve a few weeks after diet onset. Within 10 months the patient achieved full remission from symptoms as well as normalization of intestinal inflammation as evidenced by imaging data, normalization of laboratory parameters and that of the
intestinal permeability. Aside from a single dietary fault the patient strictly adhered to the diet as assessed by frequent patient feedback, laboratory data and home monitoring of urinary ketones. Given the patient’s severe condition upon the first visit the paleolithic ketogenic diet was started in the strictest form thus containing no vegetables and fruits at all. Such a diet may first sound restrictive but our previous experience indicate that a full fat-meat diet is needed in the most severe cases of Crohn’s disease. In addition, our experience shows that even a single occasion of deviation from diet rules may result in lasting relapse. This was the case in the present patient too where breaking the strict rules (eating the “paleo cakes”) resulted in a thickening of the bowel wall. Based on our experience this is due to the components of the popular paleolithic diet including coconut oil, oil seeds and sugar alcohols which may trigger inflammation. In contrast, honey, consumed in limited amounts is tolerable and does not cause such symptoms. The significant improvement seen in the last laboratory exam also indicates that the paleolithic ketogenic diet is most effective when containing no plant components at all.

Table 2: Laboratory data while on the paleolithic ketogenic diet with no medications. Dashes indicate that a given parameter was not measured.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>7.1</td>
<td>8.5</td>
<td>5.7</td>
<td>7.1</td>
<td>7.1</td>
<td>7.8</td>
<td>8.0</td>
<td>4.5–11.5 G/L</td>
</tr>
<tr>
<td>RBC</td>
<td>5.0</td>
<td>4.8</td>
<td>4.8</td>
<td>5.2</td>
<td>4.8</td>
<td>5.3</td>
<td>5.4</td>
<td>4.5–5.9 T/L</td>
</tr>
<tr>
<td>Hgb</td>
<td>145</td>
<td>135</td>
<td>137</td>
<td>147</td>
<td>135</td>
<td>146</td>
<td>151</td>
<td>135–170 g/L</td>
</tr>
<tr>
<td>Hct</td>
<td>0.42</td>
<td>0.39</td>
<td>0.4</td>
<td>0.42</td>
<td>0.39</td>
<td>0.43</td>
<td>0.44</td>
<td>0.41–0.51 L/L</td>
</tr>
<tr>
<td>Thrombocyte</td>
<td>71</td>
<td>75</td>
<td>68</td>
<td>82</td>
<td>95</td>
<td>65</td>
<td>100</td>
<td>150–400 G/L</td>
</tr>
<tr>
<td>CRP</td>
<td>3.75</td>
<td>9.9</td>
<td>9.3</td>
<td>1.8</td>
<td>14.3</td>
<td>4.4</td>
<td>7.1</td>
<td>0.5–5 mg/L</td>
</tr>
<tr>
<td>ESR</td>
<td>3.0</td>
<td>8.0</td>
<td>8.0</td>
<td>5.0</td>
<td>10.0</td>
<td>6.0</td>
<td>5.0</td>
<td>0.15 mm/h</td>
</tr>
<tr>
<td>Total protein</td>
<td>60</td>
<td>62</td>
<td>-</td>
<td>-</td>
<td>63</td>
<td>65</td>
<td>66</td>
<td>57–80 g/L</td>
</tr>
<tr>
<td>Carbohydrate</td>
<td>5.3</td>
<td>6.2</td>
<td>-</td>
<td>-</td>
<td>5.8</td>
<td>6.3</td>
<td>6.9</td>
<td>2.8–7.2 mmol/L</td>
</tr>
<tr>
<td>Creatinine</td>
<td>53</td>
<td>63</td>
<td>-</td>
<td>-</td>
<td>48</td>
<td>66</td>
<td>73</td>
<td>53–100 µmol/L</td>
</tr>
<tr>
<td>Sodium</td>
<td>141</td>
<td>138</td>
<td>-</td>
<td>-</td>
<td>139</td>
<td>140</td>
<td>139</td>
<td>135–145 mmol/L</td>
</tr>
<tr>
<td>Potassium</td>
<td>4.3</td>
<td>3.9</td>
<td>-</td>
<td>-</td>
<td>4.1</td>
<td>4.1</td>
<td>4.2</td>
<td>3.2–5.1 mmol/L</td>
</tr>
<tr>
<td>GOT</td>
<td>18.0</td>
<td>20.0</td>
<td>-</td>
<td>-</td>
<td>21.0</td>
<td>24.0</td>
<td>24.0</td>
<td>0.5–50 µmol/L</td>
</tr>
<tr>
<td>GPT</td>
<td>12.0</td>
<td>14.0</td>
<td>-</td>
<td>-</td>
<td>18.0</td>
<td>18.0</td>
<td>18.0</td>
<td>0.5–50 µmol/L</td>
</tr>
<tr>
<td>GGT</td>
<td>12.0</td>
<td>13.0</td>
<td>-</td>
<td>-</td>
<td>13.0</td>
<td>13.0</td>
<td>12.0</td>
<td>0.5–55 µmol/L</td>
</tr>
<tr>
<td>Iron</td>
<td>12.1</td>
<td>10.3</td>
<td>-</td>
<td>-</td>
<td>10.6</td>
<td>11.0</td>
<td>13.7</td>
<td>12.5–32 µmol/L</td>
</tr>
<tr>
<td>Uric acid</td>
<td>258</td>
<td>264</td>
<td>-</td>
<td>-</td>
<td>332</td>
<td>329</td>
<td>329</td>
<td>208–428 µmol/L</td>
</tr>
<tr>
<td>Glucose</td>
<td>5.0</td>
<td>5.0</td>
<td>-</td>
<td>-</td>
<td>5.3</td>
<td>5.2</td>
<td>5.4</td>
<td>3.5–6.1 mmol/L</td>
</tr>
<tr>
<td>Magnesium</td>
<td>0.76</td>
<td>0.86</td>
<td>-</td>
<td>-</td>
<td>0.81</td>
<td>0.87</td>
<td>0.89</td>
<td>0.73–1.06 mmol/L</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>4.6</td>
<td>4.9</td>
<td>4.7</td>
<td>4.8</td>
<td>4.3</td>
<td>4.1</td>
<td>4.3</td>
<td>&lt;5.2 mmol/L</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.9</td>
<td>1.46</td>
<td>-</td>
<td>-</td>
<td>0.56</td>
<td>0.93</td>
<td>1.34</td>
<td>&lt;1.7 mmol/L</td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>-</td>
<td>-</td>
<td>2.5</td>
<td>2.3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2.4 g/L</td>
</tr>
<tr>
<td>Urinary ketones</td>
<td>++</td>
<td>++</td>
<td>+++</td>
<td>+++</td>
<td>+++</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

very advanced stage. Although Crohn’s disease is known to be characterized by an alternation of better and worse periods, a complete remission from a very advanced stage is highly unlikely to be the part of the normal course of the disease.

While on the biological therapy thrombocyte number dropped and continued to decrease while on the diet. Our previous experience does not indicate thrombocytopenia on the paleolithic ketogenic diet. However, low thrombocyte number is a well-known side effect of the use of adalimumab in Crohn’s disease [14, 15]. It is also noteworthy that a return to the strictest form of the paleolithic ketogenic diet resulted in an increase in thrombocyte number.

Crohn’s disease is regarded as an autoimmune disease. Autoimmune diseases and Crohn’s disease specifically have been linked to increased intestinal permeability [16]. Yet currently there is no known means to reverse pathological intestinal permeability [17]. A previous study with the paleolithic diet found no change in intestinal permeability as assessed by the lactulose-mannitol test [18]. As far as we know this is the first documented case where pathological intestinal permeability was reversed as assessed by a diagnostic test.

Experts in the field of evolutionary medicine has long been suggesting that chronic diseases of civilization emerge from a mismatch between our ancient genome and current lifestyles [19, 20]. In recent years an increasing number of studies showed that the metabolic syndrome and associated conditions can be reversed or improved by applying a diet denoted as "paleolithic" (for a review see: [21]). In the paleolithic diet, as described in the implied papers, macronutrient ratios are undefined or variable, as well as that of the ratio of animal/plant foods including the ratio of animal/plant fats. Our clinical experience, however, indicate that the most severe chronic conditions, including the Crohn’s disease, can only be reversed by the paleolithic ketogenic diet based on animal fat, meat and offal. A same conclusion was drawn in our previous case study showing that the paleolithic ketogenic diet was more effective than the popular form of the paleolithic diet in the case of Gilbert’s syndrome [11]. The paleolithic ketogenic diet we use in the treatment of chronic diseases is close to the evolutionary diet originally proposed by gastroenterologist Voegtlin [22]. With regard to the main principals, background, sustainability and further issues such as vitamin supply while on a meat-fat based diet we refer to the excellent book of Voegtlin [22].

As regards the underlying mechanism, we put forward that normalizing pathological intestinal permeability is crucial in tackling autoimmune diseases, including Crohn’s disease. Accordingly, increased intestinal permeability has been shown to predict relapses in Crohn’s disease [23]. It is known that under physiological conditions, dietary macromolecules are not transported paracellularly from the intestinal lumen to the blood or the lymph. It has been suggested that certain components of the Western-type diet are able to destroy cell junctions and thereby compromise the intestinal barrier function [24, 25]. As a result, large molecules including protein fragments and glycoproteins, possessing antigenic properties, may appear in the circulation and promote chronic inflammation [26]. Given their specific structure, these macromolecules may bind to and form complexes with the surface molecules of certain cell types. Such a complex is then destroyed by the immune system through apoptosis [27, 28]. We assume that a continued exposition to these macromolecules may maintain the autoimmune destruction of tissues. We put forward that the animal fat-meat based diet, the only diet humans are evolutionary adapted to, is lacking substances that are destroying the intestinal barrier. A shift toward the paleolithic ketogenic diet may normalize intestinal permeability (as also seen in our patient) and thereby may halt the autoimmune destruction of the affected tissues, in our case the intestine. With the attenuation of the autoimmune process the intestine may regenerate.

CONCLUSION

We conclude that the paleolithic ketogenic diet was effective while producing no side effects in this case of Crohn’s disease. In contrast to standard therapeutic approaches which are aimed to control certain components of the disease only, the paleolithic ketogenic diet was able to reverse the cluster of symptoms and abnormalities associated with the disease. Assuming a long term dietary compliance, we believe that the patient would remain disease-free in the future.

Author Contributions

Csaba Tóth – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Andrea Dabóczi – Acquisition of data, Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Mark Howard – Acquisition of data, Analysis and interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Nicholas J. Miller – Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Zsófia Clemens – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2016 Csaba Tóth et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES

20. Lindeberg S. Food and western disease: health and nutrition from an evolutionary perspective. Chichester: Wiley-Blackwell; 2009.
Edorium Journals: An introduction

Edorium Journals Team

About Edorium Journals
Edorium Journals is a publisher of high-quality, open access, international scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

But why should you publish with Edorium Journals?
In less than 10 words - we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Our Commitment

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.*

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days). If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.*

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services.

* Terms and condition apply. Please see Edorium Journals website for more information.

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web

Browse Journals